MADRIGAL PHARMACEUTICALS, INC. quarterly report, Q2 FY2012

Business context and reporting period

Filing identity: The supplied filing is Synta Pharmaceuticals Corp.’s unaudited Form 10-Q for the quarter ended June 30, 2012, not a Madrigal Pharmaceuticals filing. The financial and operating information below pertains to Synta.

Synta was a clinical-stage biopharmaceutical company developing small-molecule drug candidates, principally ganetespib. It reported no product sales and relied on equity financing, debt, grants, and former collaboration agreements. Roche’s collaboration ended February 16, 2012.

Key financial metrics

Six-month operating cash use was $28.349 million; investing activities used $9.624 million and financing activities provided $33.491 million. Cash and cash equivalents at period-end were $25.593 million, with marketable securities of $19.063 million, or $44.656 million combined. Working capital was approximately $27.2 million. Total liabilities were $26.700 million.

Term-loan principal totaled approximately $16.316 million, bearing interest at 9.75% on the GECC loan and 13.35% on the Oxford loan. The GECC loan was secured by substantially all assets other than intellectual property, with a springing IP security interest tied to cash-usage covenant compliance. The filing reports $907,000 cash interest paid during the first half.

Changes versus prior comparable periods

• Second-quarter revenue fell from $1.354 million in 2011 to zero in 2012; first-half revenue fell from $2.497 million to $147,000. The decline primarily reflects the terminated Roche agreement and completion of the DoD grant work.
• Second-quarter net loss increased from $12.502 million to $14.620 million; first-half net loss rose from $23.903 million to $29.671 million.
• First-half R&D expense increased 18% to $23.318 million, mainly due to ganetespib trial enrollment and new trial start-up costs. Ganetespib R&D rose to $20.6 million for the half; reduced CRACM, elesclomol, and STA-9584 spending partly offset the increase.
• First-half operating cash use increased from $24.993 million to $28.349 million. Combined cash and securities were $44.656 million versus $39.725 million at December 31, 2011, following the January–February equity offering.

Outlook, commentary, risks, and unusual items

• Management expected cash resources at June 30, together with approximately $25.8 million net proceeds from a July registered direct offering, to fund operations into the second half of 2013. The estimate depended on planned activities being conducted subject to available funding. Management warned cash use could increase and additional funding could be needed earlier.
• The July offering sold 3,976,702 shares at $6.49 per share to directors, including the largest existing stockholder. Separately, the January–February offering raised approximately $33.0 million net. The company’s $35 million ATM facility had no sales as of the filing.
• Management anticipated higher ganetespib development costs in 2012 and lower CRACM and STA-9584 costs; G&A was expected to remain near 2011 levels. No product revenue was expected in the foreseeable future, if ever.
• In June, Synta reported interim GALAXY results for ganetespib plus docetaxel. Among adenocarcinoma patients, median progression-free survival was 4.2 months in the combination arm versus 2.9 months with docetaxel alone; subgroup results also favored combination treatment in the elevated-LDH and mutant-KRAS groups. These were interim findings with small subgroup samples, and the filing described them as encouraging, not definitive. Management planned further analysis, regulatory discussions, and transition to the Phase 3 portion; it anticipated Phase 2b final data in the first half of 2013 and Phase 3 final data in the first half of 2014.
• GALAXY enrollment of squamous-cell patients was stopped after lack of observed benefit and possible safety concerns, including bleeding risk. Synta described the overall evidence as preliminary; clinical efficacy and safety remained uncertain.
• Roche termination returned rights to specified compounds to Synta; potential future product sales could carry low-single-digit royalties to Roche. Synta disclosed no material legal proceedings and no material changes to its previously reported risk factors.
• A July 2012 GECC amendment delayed the potential trigger of the lender’s springing IP security interest until after August 1, 2012. The filing states no material changes to contractual obligations otherwise.

Important facts for investors to verify

1. Confirm the issuer: this is Synta Pharmaceuticals Corp., notwithstanding the Madrigal metadata.
2. Review subsequent clinical results and trial status for GALAXY, CHIARA, and ENCHANT, including whether interim GALAXY findings translated into statistically meaningful outcomes.
3. Assess cash runway against actual operating burn, trial spending, and financing needs; the runway estimate includes the July offering and is conditional.
4. Review dilution and related-party participation in the January–February and July equity offerings, plus any later ATM sales.
5. Check compliance with GECC loan covenants, repayment terms, and the status of the springing intellectual-property lien provision.